S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Bausch Health Companies Stock Price, News & Analysis (NYSE:BHC)

$22.63
+0.46 (+2.07 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$22.31
Now: $22.63
$22.78
50-Day Range
$19.10
MA: $21.45
$23.45
52-Week Range
$17.20
Now: $22.63
$27.72
Volume3.14 million shs
Average Volume3.82 million shs
Market Capitalization$7.96 billion
P/E Ratio5.63
Dividend YieldN/A
Beta0.85
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone514-744-6792

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.38 billion
Cash Flow$13.31 per share
Book Value$8.05 per share

Profitability

Net Income$-4,148,000,000.00

Miscellaneous

Employees21,100
Market Cap$7.96 billion
Next Earnings Date11/4/2019 (Confirmed)
OptionableOptionable

Receive BHC News and Ratings via Email

Sign-up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.


Bausch Health Companies (NYSE:BHC) Frequently Asked Questions

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc (NYSE:BHC) announced its quarterly earnings data on Tuesday, August, 6th. The company reported $1.03 EPS for the quarter, missing the Zacks' consensus estimate of $1.06 by $0.03. The firm earned $2.15 billion during the quarter, compared to the consensus estimate of $2.15 billion. Bausch Health Companies had a negative net margin of 10.88% and a positive return on equity of 52.12%. The firm's quarterly revenue was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.93 earnings per share. View Bausch Health Companies' Earnings History.

When is Bausch Health Companies' next earnings date?

Bausch Health Companies is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Bausch Health Companies.

How can I listen to Bausch Health Companies' earnings call?

Bausch Health Companies will be holding an earnings conference call on Monday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies updated its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $8.4-8.6 billion, compared to the consensus revenue estimate of $8.49 billion.

What price target have analysts set for BHC?

16 Wall Street analysts have issued 1-year target prices for Bausch Health Companies' shares. Their predictions range from $9.00 to $54.00. On average, they expect Bausch Health Companies' share price to reach $29.85 in the next year. This suggests a possible upside of 31.9% from the stock's current price. View Analyst Price Targets for Bausch Health Companies.

What is the consensus analysts' recommendation for Bausch Health Companies?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 2 sell ratings, 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bausch Health Companies.

What are Wall Street analysts saying about Bausch Health Companies stock?

Here are some recent quotes from research analysts about Bausch Health Companies stock:
  • 1. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We employ a cash EPS multiple-based approach. The cash EPS number is derived from our adjusted 12-month income, which employs a total 12-month adjusted (non-GAAP) income projection of roughly $1.6B, which we divide by approximately 357M shares outstanding to derive our 12-month cash EPS of $4.46 per share." (8/7/2019)
  • 2. According to Zacks Investment Research, "Although Bausch’s performance in the first quarter was mixed, we are pretty encouraged by the increase in the company’s guidance. Growth in Xifaxan sales, the launch of Bryhali, the successful acquisition of Trulance and the approval of Duobrii should boost performance, going forward. Even though it is still early to comment on the rebuilding process, the company’s efforts to sell non-core assets and pay down huge levels of debt are commendable. Bausch repaid $100 million of debt in the first quarter of 2019 after repaying more than $1 billion in 2018. However, the dermatology market continues to be challenging. Shares have outperformed the industry in the year so far. " (5/21/2019)
  • 3. Cantor Fitzgerald analysts commented, "We rate BHC as 12-month price target of $32. A greater appreciation for BHC’s solid execution and future growth prospects under the new management team should drive upwards earnings revisions in 2019+, multiple expansion, and BHC shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $32." (4/25/2019)

Has Bausch Health Companies been receiving favorable news coverage?

News headlines about BHC stock have been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bausch Health Companies earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Bausch Health Companies.

Are investors shorting Bausch Health Companies?

Bausch Health Companies saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 9,140,000 shares, a decline of 9.7% from the August 30th total of 10,120,000 shares. Based on an average daily trading volume, of 3,080,000 shares, the days-to-cover ratio is currently 3.0 days. Approximately 2.6% of the company's shares are short sold. View Bausch Health Companies' Current Options Chain.

Who are some of Bausch Health Companies' key competitors?

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Constellation Software (CSU), Intact Financial (IFC), Gilead Sciences (GILD), Micron Technology (MU), Twitter (TWTR), Alibaba Group (BABA), Netflix (NFLX), Bank of America (BAC), NVIDIA (NVDA) and Tesla (TSLA).

Who are Bausch Health Companies' key executives?

Bausch Health Companies' management team includes the folowing people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 64)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 63)
  • Mr. Thomas J. Appio, Pres & Co-Head Bausch + Lomb/International (Age 57)
  • Mr. William D. Humphries, Pres of Ortho-Dermatologics (Age 53)
  • Mr. Osama A. Eldessouky, Sr. VP, Controller & Chief Accounting Officer (Age 47)

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by a number of of retail and institutional investors. Top institutional investors include Commerzbank Aktiengesellschaft FI (0.30%), Cullinan Associates Inc. (0.01%), Nisa Investment Advisors LLC (0.01%), Fox Run Management L.L.C. (0.01%), Crossmark Global Holdings Inc. (0.01%) and SeaCrest Wealth Management LLC (0.00%). Company insiders that own Bausch Health Companies stock include Christina Ackermann, John Paulson, Joseph C Papa, Mark C Mckenna, Paul Herendeen, Schutter Richard U De, Thomas Appio and William D Humphries. View Institutional Ownership Trends for Bausch Health Companies.

Which major investors are selling Bausch Health Companies stock?

BHC stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Gulf International Bank UK Ltd and SeaCrest Wealth Management LLC. Company insiders that have sold Bausch Health Companies company stock in the last year include Christina Ackermann and Mark C Mckenna. View Insider Buying and Selling for Bausch Health Companies.

Which major investors are buying Bausch Health Companies stock?

BHC stock was bought by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Nisa Investment Advisors LLC, Fox Run Management L.L.C. and Cullinan Associates Inc.. Company insiders that have bought Bausch Health Companies stock in the last two years include John Paulson, Joseph C Papa, Paul Herendeen, Schutter Richard U De, Thomas Appio and William D Humphries. View Insider Buying and Selling for Bausch Health Companies.

How do I buy shares of Bausch Health Companies?

Shares of BHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $22.63.

How big of a company is Bausch Health Companies?

Bausch Health Companies has a market capitalization of $7.96 billion and generates $8.38 billion in revenue each year. The company earns $-4,148,000,000.00 in net income (profit) each year or $4.02 on an earnings per share basis. Bausch Health Companies employs 21,100 workers across the globe.View Additional Information About Bausch Health Companies.

What is Bausch Health Companies' official website?

The official website for Bausch Health Companies is http://www.bauschhealth.com/.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company can be reached via phone at 514-744-6792 or via email at [email protected]


MarketBeat Community Rating for Bausch Health Companies (NYSE BHC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  282 (Vote Underperform)
Total Votes:  534
MarketBeat's community ratings are surveys of what our community members think about Bausch Health Companies and other stocks. Vote "Outperform" if you believe BHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Featured Article: What is a Roth IRA?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel